To enable widespread patient access to lifesaving cell and gene therapies, you need both superior biological performance and the benefits of digitally enabled automation to maximize your clinical and commercial impact. Explore IRO®See The Data Begin With Biology Ori has taken a biology-first approa...
LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) --Oribiotech Ltd.(Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the first customer deliveries of the new IRO®platform, specifically designed to help address the curr...
芯行纪科技有限公司(X-Times Design Automation Co., LTD)汇聚全球一流EDA技术支持和研发精英,着力于自主研发新一代数字芯片实现EDA技术和提供高端数字芯片设计解决方案,可大幅度提升芯片设计效率,并助力实现芯片一次性快速量产,在人工智能、智能汽车、5G、云计算等集成电路领域为众多合作伙伴的高速发展和产业腾飞保驾护航。
Endpoints Cell and Gene DaySee all events Today, only a small percentage of patients are able to access lifesaving cell and gene therapies. These therapies are too hard to manufacture, Too expensive to make widely available, And not commercially viable due to high costs, low throughput, and ...